Hepatitis
From the Journals
Insurer denials of DAA therapy for HCV on the rise
About one in three patients had lack of fill approval by insurers.
News
CDC warns of hepatitis A outbreaks in injection drug users
Gap in vaccine availability now has been solved.
Video
VIDEO: Hepatitis C eradication cuts nonliver cancer rate
WASHINGTON - U.S. data from thousands of treated hepatitis C patients implicates the virus as carcinogenic and a factor in a wide range of...
From the Journals
Scoring system quantified chances of HCV treatment benefit
Does a new scoring system hold the promise of avoiding 'MELD purgatory'?
From the Journals
Alcohol abuse untreated in HCV patients, including HIV coinfected
HCV patients with alcohol-use disorder often don’t get the treatment they need.
Conference Coverage
CKD triples risk of bad outcomes in HIV
BOSTON – Smoking, diabetes, dyslipidemia, low body mass index, and poor HIV control were modifiable risk factors for CKD.
Conference Coverage
How to choose between highly effective HBV therapies
The newest drug, tenofovir alafenamide, has the edge in its safety profile for treating chronic hepatitis B infection.
Conference Coverage
Where the latest HCV drug combos fit in
MAUI, HAWAII – The biggest remaining challenge in the treatment of hepatitis C is to gain improved access to therapy, according to Steven L. Flamm...
From the Journals
Very few infants born to HCV-infected mothers receive testing
Despite increasing prevalence of hepatitis C virus infection in pregnant women, infants exposed to the disease are screened at a very low rate.
Conference Coverage
New drugs provide new options in HCC
PHILADELPHIA – “We are on the cusp where new compounds not only are being tested, but they are being approved.”
Conference Coverage
Treatment of HCV in special populations
MAUI, HAWAII – Acute hepatitis C infection sometimes warrants treatment.